Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Daniel S. Chen's publication output changed over time?
ScholarIQpublication output · 2013–2020
Output grew0% over the shown period — from 1 works in 2013 to 1 in 2020.
1
2
2
1
1
1
201320142016201720182020
What are the most-cited papers on Daniel S. Chen?
ScholarIQmost cited works
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen, Ira Mellman
Immunity. 20136,979 CitationsOPEN ACCESS
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E. Kadel, Hartmut Koeppen, Jillian L. Astarita, Rafael Cubas, Suchit Jhunjhunwala, Romain Banchereau, Yagai Yang, Yinghui Guan, Cécile Chalouni, James Ziai, Yasin Şenbabaoğlu, Stephen P. Santoro, Daniel Sheinson, Jeffrey Hung, Jennifer M. Giltnane, Andrew A. Pierce, Kathryn Mesh, Steve Lianoglou, Johannes Riegler, Richard A.D. Carano, Pontus Eriksson, Mattias Höglund, Loan Somarriba, Daniel L. Halligan, Michiel S. van der Heijden, Yohann Loriot, Jonathan E. Rosenberg, Lawrence Fong, Ira Mellman, Daniel S. Chen, Marjorie Green, Christina Louise Derleth, Gregg Fine, Priti S. Hegde, Richard Bourgon, Thomas Powles
Nature. 20185,569 Citations
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Nature. 20175,387 Citations
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi
Nature. 20145,287 Citations
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
The Lancet. 20164,789 CitationsOPEN ACCESS
Related on ScholarIQ
Oncology Meets Immunology: The Cancer-Immunity Cycle
Paper
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Paper
Elements of cancer immunity and the cancer–immune set point
Paper
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Paper
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Paper
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Paper